Core Insights - Assertio Holdings, Inc. announced new data from a real-world study of SYMPAZAN (clobazam) Oral Film, highlighting its application in treating patients with Lennox-Gastaut Syndrome (LGS) [1][2][6] - The study provides valuable insights into the demographics, medication use, and comorbidities of patients with epilepsy or LGS using clobazam oral film [3][7] Group 1: Study Findings - The study identified 181 patients with epilepsy, including 29 patients specifically with LGS, using electronic health records from Stanford Health Care between 2015 and 2024 [3][4] - Patients in the LGS subset were younger (average age 13.6 years) compared to the overall epilepsy group (average age 21.1 years) and showed higher rates of switching from clobazam tablets or suspension [7] Group 2: Clinical Implications - The findings support the role of the oral film formulation in treating LGS patients who have difficulty swallowing, providing a practical solution for this patient population [2][6] - The study aims to enhance the medical community's understanding of how to incorporate SYMPAZAN into treatment regimens for LGS patients [2][3] Group 3: Product Information - SYMPAZAN is the only FDA-approved oral film formulation of clobazam for the adjunctive treatment of seizures associated with LGS in patients aged two years and older [10][11] - The oral film is available in 5 mg, 10 mg, and 20 mg dosages, designed to meet the needs of patients who may struggle with traditional tablet forms [10]